Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavodelpar - Reneo Pharmaceuticals

Drug Profile

Mavodelpar - Reneo Pharmaceuticals

Alternative Names: HPP 593; REN-001 - Reneo Pharmaceuticals

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer High Point Pharmaceuticals; Reneo Pharmaceuticals; vTv Therapeutics LLC
  • Class Acetic acids; Alkenes; Alkynes; Antihyperglycaemics; Antihyperlipidaemics; Fluorobenzenes; Morpholines; Phenyl ethers; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial myopathies; Inborn error metabolic disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Inborn error metabolic disorders; Mitochondrial myopathies
  • Discontinued Diabetes mellitus; Dyslipidaemias; Glycogen storage disease type V; Muscle fatigue

Most Recent Events

  • 09 Feb 2024 Reneo Pharmaceuticals terminates the phase II/III STRIDE AHEAD trial for Mitochondrial myopathies in Australia, Germany, Denmark, Hungary, Belgium, Netherlands, Spain, Canada, France, Italy, New Zealand and United Kingdom (PO), because the parent study failed to show therapeutic effect (NCT05267574) (EudraCT2021-003471-34)
  • 31 Dec 2023 Mavodelpar - Reneo Pharmaceuticals is available for licensing as of 31 Dec 2023. https://reneopharma.com/
  • 14 Dec 2023 Suspended - Phase-I for Inborn error metabolic disorders in France (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top